|
|
|
|
| LEADER |
03171nmm a2200337 u 4500 |
| 001 |
EB002210613 |
| 003 |
EBX01000000000000001347813 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
240603 ||| eng |
| 020 |
|
|
|a 9789819701469
|
| 100 |
1 |
|
|a Arjmand, Farukh
|
| 245 |
0 |
0 |
|a Advances and Prospects of 3-d Metal-Based Anticancer Drug Candidates
|h Elektronische Ressource
|c by Farukh Arjmand, Sartaj Tabassum, Huzaifa Yasir Khan
|
| 250 |
|
|
|a 1st ed. 2024
|
| 260 |
|
|
|a Singapore
|b Springer Nature Singapore
|c 2024, 2024
|
| 300 |
|
|
|a XII, 284 p. 1 illus
|b online resource
|
| 505 |
0 |
|
|a 1. Introduction -- 2. Classification of Metal-Based Anticancer Chemotherapeutic Agents -- 3. Interaction Studies of Metal-Based Anticancer Drug Entities with Potential Therapeutic Targets -- 4. Biophysical and Spectroscopic Techniques to Validate the Interaction with Therapeutic targets -- 5. DNA Condensation Processes mediated by Metal-based Drug Entities and Morphological Studies -- 6. Molecular Docking and Computational in silico Investigations of Metal-Based Drug Agents -- 7.Biochemical Mechanistic Pathway of Cell Death Induced by Metal-Based Chemotherapeutic Agents -- 8.Combination Drug Strategies for Targeting Specific Biochemical Pathways for Superior Therapeutic Potency -- 9. Advanced Drug Delivery Strategies for Metal-Based Anticancer Drugs -- 10. Endoplasmic Reticulum(ER) Targeted Metal-Based Anticancer Chemotherapeutic Agents -- 11.Progress and Future Projections in Metal-Based Polymeric Anticancer Compounds -- 12. Conclusions
|
| 653 |
|
|
|a Metabolism
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Cancer Therapy
|
| 653 |
|
|
|a Biochemistry
|
| 653 |
|
|
|a Cancer / Treatment
|
| 653 |
|
|
|a Cancer Metabolism
|
| 700 |
1 |
|
|a Tabassum, Sartaj
|e [author]
|
| 700 |
1 |
|
|a Khan, Huzaifa Yasir
|e [author]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-981-97-0146-9
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-981-97-0146-9?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a This book reviews the potential of metallodrugs against different cancer. It summarizes the classification of metal-based anti-cancer drugs, their plausible biochemical and mechanistic pathways, combining drug strategies for hitting multiple therapeutic targets at the intracellular level, and advanced drug delivery strategies. The book covers the metallodrugs for the efficacious treatment of diverse cancerous strains and recent advances in drug delivery strategies that are used for developing these metal-based therapeutics as potent anticancer agents in vitro and in vivo. The book also covers different biophysical and analytical techniques for studying metal-ligand and metal-macromolecular interactions. The book further presents the recent examples of metallomics studies on the different types of cell death induced by metal-based anticancer drugs, especially on the three major forms of programmed cell death (PCD) in mammalian cells: apoptosis, autophagy, and regulated necrosis, also called necroptosis. Lastly, the book explores the modulation of reactive oxygen species (ROS) by metallodrugs
|